
Revolution Medicines (RVMD) Stock Forecast & Price Target
Revolution Medicines (RVMD) Analyst Ratings
Bulls say
Revolution Medicines is well-positioned to capitalize on the large and growing market for targeted therapies in the precision oncology space, with a robust pipeline of direct and companion inhibitors targeting RAS-addicted cancers. The company's recent positive data for its RAS(ON) inhibitors and promising clinical collaborations, coupled with its strong financial position, make it an attractive investment opportunity in the oncology therapeutics sector.
Bears say
Revolution Medicines is facing fierce competition in the field of RAS-targeted cancer therapies, with multiple other RAS G12C inhibitors in development by larger pharmaceutical companies. Additionally, while the initial data for their lead candidate shows promise, it is still early and the efficacy and safety profile compared to established treatments remains to be seen. This, combined with the company's relatively limited pipeline and partnership-based business model, make it a risky investment at this time.
This aggregate rating is based on analysts' research of Revolution Medicines and is not a guaranteed prediction by Public.com or investment advice.
Revolution Medicines (RVMD) Analyst Forecast & Price Prediction
Start investing in Revolution Medicines (RVMD)
Order type
Buy in
Order amount
Est. shares
0 shares